Bimekizumab as treatment for moderate to severe chronic plaque psoriasis: Real world clinical experience from a district general hospital setting.
作者信息
Ashaolu Omowunmi, Smith Tracy, Askins Amie, Rajan Suchitra, Li Vincent, Kamath Sandeep, Hughes Jenny, Haebich Geraldine
机构信息
Department of Dermatology Princess of Wales Hospital Bridgend UK.
出版信息
Skin Health Dis. 2024 Jun 27;4(5):e418. doi: 10.1002/ski2.418. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
Bimekizumab as treatment for moderate to severe chronic plaque psoriasis: Real world clinical experience from a district general hospital setting.比美吉珠单抗治疗中度至重度慢性斑块状银屑病：来自一家区综合医院的真实世界临床经验。
Skin Health Dis. 2024 Jun 27;4(5):e418. doi: 10.1002/ski2.418. eCollection 2024 Oct.
2
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).比美吉珠单抗治疗斑块状银屑病的有效性和安全性：一项真实世界多中心研究-IL PSO（意大利银屑病情况）
Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.
3
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).比美吉珠单抗治疗老年患者的疗效和安全性：真实世界多中心回顾性研究-IL PSO（意大利银屑病景观）。
J Dermatolog Treat. 2024 Dec;35(1):2393376. doi: 10.1080/09546634.2024.2393376. Epub 2024 Aug 20.
4
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.比美克珠单抗治疗中重度斑块状银屑病患者的安全性：来自 2 期和 3 期随机临床试验的汇总结果。
JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185.
5
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials.比美吉珠单抗治疗中度至重度斑块状银屑病：一项随机临床试验的荟萃分析
Ther Adv Chronic Dis. 2023 Apr 4;14:20406223231163110. doi: 10.1177/20406223231163110. eCollection 2023.
6
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.中度至重度斑块状银屑病患者的比美吉珠单抗治疗：药物安全性评估
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):355-362. doi: 10.1080/14740338.2023.2218086. Epub 2023 Jun 19.
7
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.比美吉珠单抗治疗斑块状银屑病：聚焦患者选择与展望
Patient Prefer Adherence. 2023 Jun 30;17:1541-1549. doi: 10.2147/PPA.S350760. eCollection 2023.
8
Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.比美吉珠单抗治疗银屑病：一项真实世界环境下评估短期和中期疗效及安全性的单中心研究。
Arch Dermatol Res. 2024 Apr 25;316(5):133. doi: 10.1007/s00403-024-02868-7.
9
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性（BE READY）：一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.
10
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
引用本文的文献
1
Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis.与比美吉珠单抗治疗中度至重度斑块状银屑病相关的不良事件：一项回顾性、多中心、事后分析。
JAAD Int. 2025 Mar 18;20:54-55. doi: 10.1016/j.jdin.2025.02.001. eCollection 2025 Jun.
本文引用的文献
1
Bimekizumab for the Treatment of Psoriasis.比美吉珠单抗治疗银屑病。
Drugs. 2021 Oct;81(15):1751-1762. doi: 10.1007/s40265-021-01612-z. Epub 2021 Oct 8.
2
Psoriasis: from Pathogenesis to Targeted Therapies.银屑病：从发病机制到靶向治疗。
Clin Rev Allergy Immunol. 2018 Feb;54(1):102-113. doi: 10.1007/s12016-018-8668-1.
3
Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.白细胞介素-17（IL-17）抑制剂治疗斑块状银屑病的综述
Skin Therapy Lett. 2015 Jan-Feb;20(1):1-5.
Zotero 插件